Company / Working Capital
Gilead Sciences Working Capital History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$6.5B
FY2025
5-year range
$3.2B / $7.2B
FY2021-FY2025
Trend
-8.9%
vs FY2024
Sector context
#5 of 213
Health Care
What the data says
Among 213 Health Care companies, Gilead Sciences is in the top 2% for working capital. Working Capital has fluctuated over the past 10 years, ranging from $3.2B in FY2021 to $25.2B in FY2018.
Based on SEC 10-K filings.
$6.5B in FY2025 with a 5-year CAGR of +7.3%. Top quartile in the Health Care sector.
Improved from $4.8B to $6.5B over the past 2 years.
Health Care sector context is included.
Working Capital over time
Growth rates
- 3-Year CAGR
- +26.8%
- 5-Year CAGR
- +7.3%
- 10-Year CAGR
- -
Sector benchmark
Top 2% in Health CareTop 2% of 213This company $6.5B Sector average $934.6M
▼
+598.6% above sector average
Key checks
Key Insights
- 5-year CAGR of +7.3%, indicating consistent growth.
- In FY2025, working capital decreased 8.9% year-over-year.
- Ranks #5 out of 213 companies in the Health Care sector.
- Peak working capital was recorded in FY2018.
Company context
Key Data Points
- Strong profit margin: 27.9%
- Strong return on equity: 37.6%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $6.5B | -8.9% |
| FY2024 | $7.2B | +49.2% |
| FY2023 | $4.8B | +49.9% |
| FY2022 | $3.2B | +1.4% |
| FY2021 | $3.2B | -31.2% |
| FY2020 | $4.6B | -77.6% |
| FY2019 | $20.5B | -18.6% |
| FY2018 | $25.2B | +25.0% |
| FY2017 | $20.2B | +79.8% |
| FY2016 | $11.2B | -24.5% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026